摘要
目的探讨不同剂量阿立哌唑治疗利培酮所致女性精神分裂症患者高催乳素血症的疗效及安全性。方法采用随机数字法将60例利培酮所致高催乳素血症的女性精神分裂症患者分为阿立哌唑5mg/d(A组)和10mg/d(B组)治疗组各30例,原利培酮治疗方案维持不变,观察疗程12周。分别于治疗前、12周末检测患者血清催乳素水平,同时采用简明精神评定量表(BPRS)和副反应量表(TESS)评定临床症状和不良反应。结果①治疗12周末,A、B两组患者血清催乳素水平较治疗前均下降,差异有统计学意义(t=27.63,P<0.01;t=26.26,P<0.01),而两组间比较差异无统计学意义(t=1.36,P=0.18)。②两组治疗前后BPRS评分差异无统计学意义(t=1.86,P=0.07;t=1.80,P=0.08)。③两组不良反应发生率差异无统计学意义(χ2=0.12,P=0.73)。结论阿立哌唑每日5mg或10mg都可能对利培酮所致女性精神分裂症患者高催乳素血症有效,对精神分裂症临床症状的影响及不良反应相当。
Objective To explore the efficacy and safety of different doses of aripiprazole on hyperprolactinemia caused by risperidone in female patients with schizophrenia. Methods 60 cases of female schizophrenic patients with hyperprolaetinemia induced by risperidone were randomly divided into aripiprazole 5mg/d （group A） and 10mg/d （ group B）treatment group with 30 cases in each group ,the original risperidone in treatment of plan unchanged for 12 weeks, the blood prolaetin level was measured at the baseline and at the end of 12th week, at the same time clinical symptoms and adverse reaction were assessed with the Brief psychiatric rating scale（BPRS） and the treatment emergene symptoms scale （TESS）. Results ①The 12 weeks after treatment, the A, B serum prolactin levels in two groups were decreased, and the difference was statistically significant （ t = 27.63, P 〈 0. 01 ; t = 26. 26,P 〈0. 01 ）. there was no significant difference between the two groups （t = 1.36, P = 0. 18 ）②There was no significant changes on the total scores of BPRS before and after treatment in the two groups （ t = 1.86,P = 0. 07 ; t = 1.80, P = 0.08 ）. ③Adverse reactions of two groups show no significant difference （x2 = 0. 12, P = 0.73 ）. Conclusion Aripiprazole （ 5 mg/d, 10mg/d） is effective and safe on hyperprolactinemia caused by risperidone in female patients with schizophrenia , and the efficacy among two groups are equivalent.
出处
《四川精神卫生》
2013年第3期223-225,共3页
Sichuan Mental Health
